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There is increasing interest in the role of epigenetic alterations in Alzheimer’s disease
(AD). The epigenome of every cell type is distinct, yet data regarding epigenetic
change in specific cell types in aging and AD is limited. We investigated histone
tail modifications in neuronal subtypes in wild-type and APP/PS1 mice at 3 (pre-
pathology), 6 (pathology-onset) and 12 (pathology-rich) months of age. In neurofilament
(NF)-positive pyramidal neurons (vulnerable to AD pathology), and in calretinin-labeled
interneurons (resistant to AD pathology) there were no global alterations in histone
3 lysine 4 trimethylation (H3K4me3), histone 3 lysine 27 acetylation (H3K27ac) or
histone 3 lysine 27 trimethylation (H3K27me3) in APP/PS1 compared to wild-type
mice at any age. Interestingly, age-related changes in the presence of H3K27ac and
H3K27me3 were detected in NF-labeled pyramidal neurons and calretinin-positive
interneurons, respectively. These data suggest that the global levels of histone
modifications change with age, whilst amyloid plaque deposition and its sequelae do
not result in global alterations of H3K4me3, H3K27ac and H3K27me3 in NF-positive
pyramidal neurons or calretinin-labeled interneurons.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by the
accumulation of intracellular tau in neurofibrillary tangles and neuropil threads, and the deposition
of insoluble extracellular β-amyloid (Aβ) plaques associated with dystrophic neurites and synapse
loss (Braak and Braak, 1991; Thal et al., 2002). A specific subset of excitatory pyramidal neurons
that express neurofilament (NF) proteins are particularly susceptible to neurofibrillary tangle
formation, dystrophic neurite formation, synapse loss, degeneration and death in AD (Hof et al.,
1990; Thangavel et al., 2009; Mitew et al., 2013a,b). In comparison, inhibitory interneurons are
relatively resistant to AD pathology (Hof and Morrison, 1991; Hof et al., 1993; Mitew et al., 2013a;
Mitew et al., 2013b).
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AD has a complex etiology including many lifestyle-related
risk factors, the greatest of which is increasing age. As the
interface between our genes and the environment, the epigenome
is well positioned to provide a mechanistic link in the onset and
progression of AD. There is increasing evidence that epigenetic
alterations occur in the aging brain and AD (Gräff et al., 2012;
Chouliaras et al., 2013; Lister et al., 2013; Ziller et al., 2013;
Coppieters et al., 2014; De Jager et al., 2014; Lunnon et al.,
2014; Benito et al., 2015; Gjoneska et al., 2015; Mastroeni
et al., 2015; Gasparoni et al., 2018; Nativio et al., 2018), and
that epigenetic changes occur early in AD and change in
tandem with disease progression (De Jager et al., 2014; Lunnon
et al., 2014; Sanchez-Mut et al., 2014; Gasparoni et al., 2018).
However, most studies analyze brain homogenate and little is
known about the epigenetic alterations that occur in specific cell
types in AD.
The epigenome is a highly interactive network of chemical
moieties including DNA methylation and histone modifications
that governs the packaging of DNA into chromatin within
the nucleus. The basic repeating unit of chromatin is the
nucleosome, which is comprised of an octamer of alkaline
histone proteins, typically canonical H2A, H2B, H3 and H4,
which form dimers and exhibit protruding N-terminal tails
that are subject to post-translational modification (Phillips and
Johns, 1965; Kornberg, 1974; Thomas and Kornberg, 1975).
The type of histone proteins present in a nucleosome and the
various post-translational modifications (including methylation
and acetylation) determine the affinity with which DNA is
bound in the nucleosome, serve to recruit histone reader and
modifier proteins and thus, modulate the accessibility of DNA
for transcription (Allfrey and Mirsky, 1964; Allfrey et al.,
1964). Thus, different histone modifications mark signatures
are associated regions of DNA that are accessible and active,
or compact and repressed (Barski et al., 2007; Heintzman
et al., 2007). For instance, trimethylation of histone 3 at
lysine 4 (H3K4me3) marks active promoters, H3K27ac marks
active promoters and enhancers, while H3K27me3 marks
repressed promoters (Cao et al., 2002; Bernstein et al., 2005;
Creyghton et al., 2010).
The epigenetic signature and gene expression profile of
each cell type is unique and there is increasing interest
in identifying cell-type specific epigenetic phenotypes in the
brain. The vast majority of studies investigating epigenetic
alteration in AD have used whole brain homogenate containing
both neurons and glia (Gräff et al., 2012; Chouliaras et al.,
2013; Coppieters et al., 2014; De Jager et al., 2014; Lunnon
et al., 2014; Sanchez-Mut et al., 2014; Gjoneska et al., 2015;
Nativio et al., 2018), likely given the technical complexity
of isolating individual cell types from brain tissue. Several
recent studies have highlighted the importance of examining
purified neurons and glia; as neurons and glia exhibit distinct
epigenetic profiles that responded differently to amyloid plaque
pathology and therapeutic interventions (Kozlenkov et al.,
2014; Benito et al., 2015; Gasparoni et al., 2018; Zhao
et al., 2018). Furthermore, diverse and highly distinctive
epigenomic signatures have been detected in neuronal subsets,
including excitatory neurons and inhibitory interneurons (Mo
et al., 2015; Kozlenkov et al., 2016; Luo et al., 2017).
Examining epigenetic marks in subpopulations of neurons
is particularly important in AD, as NF-positive pyramidal
neurons are particularly susceptible to dysfunction, degeneration
and death in AD (Hof et al., 1990; Thangavel et al., 2009;
Mitew et al., 2013a,b).
While numerous studies have identified DNA methylation
alterations in aging and AD (Chouliaras et al., 2013; Lister
et al., 2013; Sanchez-Mut et al., 2013, 2014; Ziller et al., 2013;
Coppieters et al., 2014; De Jager et al., 2014; Lunnon et al.,
2014; Gasparoni et al., 2018), there are relatively few studies
that have investigated histone modifications in AD and in aged
neurons (Benito et al., 2015; Gjoneska et al., 2015; Mastroeni
et al., 2015; Narayan et al., 2015; Nativio et al., 2018). To
date, dysregulation of the H4K16ac, H3K4me3, H4K12ac and
H3K27ac histone marks have been reported in human AD
and in mouse models of AD. In the temporal gyrus of AD
cases, there was a dysregulation of H4K16ac peaks in AD
including both gains and losses that were associated with
pathways including signaling cascades, apoptosis/cell death and
cell communication (Nativio et al., 2018). Similarly, significant
alterations in H3K4me3 in promotor regions and H3K27ac at
enhancer regions (including gains and losses) associated with
increased immune system processes and decreased synaptic
transmission, learning and memory were identified in the
hippocampus of the CK-p25 mouse model of neurodegeneration
(Gjoneska et al., 2015). However, in the hippocampus and
medial temporal gyrus of human AD cases, there was no
alteration in overall H3K4me3 protein levels detected, however
a decrease in nuclear H3K4me3 concomitant with increased
abnormal cytoplasmic H3K4me3 was observed (Mastroeni
et al., 2015). Finally, a study by Benito et al. (2015) reported
a decrease in H4K12ac at the transcriptional start site of
neuronal and non-neuronal cells in transgenic (TG) AD model
mice that was associated with the downregulation of synaptic
plasticity genes in the hippocampus. Notably, there are only
two published articles to date (Benito et al., 2015; Mastroeni
et al., 2015) examining histone mark alterations specifically in
neurons in AD.
We investigate the histone marks H3K4me3, H3K27ac
and H3K27me3 in APP/PS1 and wild-type mice at 3, 6 and
12 months of age, representing pre-pathology, pathology
onset and pathology-rich time points in this mouse model.
APP/PS1 mice are a well-characterized mouse model of
amyloid deposition that develop Aβ plaques, plaque-associated
dystrophic neurites, synapse loss and memory deficits with
age (Jankowsky et al., 2004; Garcia-Alloza et al., 2006;
Kilgore et al., 2010; Volianskis et al., 2010; Mitew et al.,
2013a,b). Differences in the vulnerability of NF-labeled
pyramidal neurons and calretinin-positive interneurons have
also been demonstrated in APP/PS1 mice. For example,
twice the proportion of NF-labeled neurites in the vicinity
of Aβ plaques exhibited neuritic dystrophy compared to
calretinin-labeled neurites in APP/PS1 mice (Mitew et al.,
2013b), and loss of excitatory, but not inhibitory, presynaptic
puncta was observed adjacent to plaques in APP/PS1 mice
(Mitew et al., 2013a). Thus, we examine histone alterations
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in disease-resistant calretinin-labeled interneurons and the
vulnerable NF-positive pyramidal neurons for the first time in
APP/PS1 mice.
MATERIALS AND METHODS
Mouse Cohort
All experiments were approved by the Animal Ethics
Committee of the University of Tasmania (#A12780/A15170)
and were undertaken according to the Australian Code
of Practice for the Care and Use of Animals for Scientific
Purposes. TG APP/PS1 mice expressing APP with the
familial Swedish mutation (KM670/671NL) and mutant
PS1 (PSENdE9; APP/PS1) under the prion protein promoter
on a C57BL/6 background strain (Jankowsky et al., 2004).
Amyloid plaques and memory deficits appear at 6 months of
age (Jankowsky et al., 2004; Kilgore et al., 2010) and plaque load
increases up to 12 months of age (Garcia-Alloza et al., 2006). By
12 months of age APP/PS1 mice exhibit spatial memory deficits,
and significant plaque-associated dystrophic neurite pathology
and excitatory synapse loss of age (Volianskis et al., 2010; Mitew
et al., 2013a,b). Neuronal loss has been reported adjacent to
amyloid plaques in 8–10-month-old APP/PS1 mice (Jackson
et al., 2016), but does not recapitulate the extensive neuronal loss
observed in human AD.
Male APP/PS1mice aged 3months (n= 10), 6months (n= 10)
and 12 months (n = 9) and age matched C57BL/6 wild-type mice
(n = 10 of each age) were used in this study. All animals were
housed in standard laboratory conditions (25◦, 12 h light/dark
cycle) with ad libitum access to food and water.
Genotyping of wild-type and APP/PS1 mice was performed
as previously (Fernandez-Martos et al., 2015). Briefly, mouse
tail genomic DNA was extracted using the Extract-N-
Amp Tissue PCR Kits (Sigma-Aldrich) and then, standard
polymerase chain reaction (PCR) analysis was performed using
MyTaqTM DNA Polymerase (Bioline) with primers to mouse
presenilin-1 (For: 5′-AATAGAGAACGGCAGGAGCA-3′;
Rev: 5′-GCCATGAGGGCACTAATCAT-3′) and interleukin
2 (For: 5′-CTAGGCCACAGAATTGAAAGATCT-3′; Rev:
5′-GTAGGTGGAAATTCTAGCATCATCC-3′) as an internal
control. Reactions (10 µL) consisted of 1 µL DNA template
and primers at a final concentration of 0.5 µM. Cycling was
performed as follows: hold at 94◦C for 2 min followed by
10 cycles of [94◦C for 20 s 65◦C (decreasing by 0.5◦C per
cycle) for 15 s and 68◦C for 10 s] followed by 28 cycles of
(94◦C for 15 s 60◦C for 15 s and 72◦C for 10 s) followed by
a hold at 72◦C for 2 min and then at 10◦C. Amplified PCR
products were then visualized by agarose gel electrophoresis
to determine genotypes. In addition, one tissue section from
each mouse used in this study was stained with Thioflavine S
and visualized on an Olympus BX50 fluorescent microscope
to confirm the genotyping data. To perform Thioflavine S
staining, tissue sections were incubated in 0.125% Thioflavine
S dissolved in a solution of 40% ethanol and 60% 0.01M
phosphate buffered saline (PBS) for 3 min on an orbital shaker
at room temperature, tissue sections were then washed twice
in a 50:50 solution of ethoanol:0.01M PBS for 1 min each,
followed by three washes in 0.01M PBS for 10 min each on an
orbital shaker.
Immunohistochemistry
Mice were anaesthetized with 150 µL of 60mg/mL sodium
pentobarbitone and transcardially perfused with 4%
paraformaldehyde in 0.1M PBS. Brain tissue was cryoprotected
(18% then 30% sucrose in PBS) and 40 µm serial coronal
sections were cut on a cryostat (Leica CM1850 cryostat with
O.C.T compound; ProSciTech, Australia).
Double-label immunohistochemistry was performed
to assess the alterations in the histone marks H3K4me3,
H3K27me3 and H3K27ac in NF-containing pyramidal neurons
(using anti-SMI32) and in calretinin-positive interneurons
(using an anti-calretinin antibody; Table 1). One coronal
section between bregma 1.53 mm and −1.56 mm containing
the S1/S2 somatosensory cortex and the M1/M2 motor
cortex from each mouse was immunolabeled with each
antibody combination. The analysis was performed in the
S1/S2 somatosensory cortex and the M1/M2 motor cortex as
significant Aβ plaque deposition, dystrophic neurite pathology
and plaque-associated synaptic loss occur in these brain
regions in APP/PS1 mice (Mitew et al., 2013a; Fernandez-
Martos et al., 2015). Double-label immunohistochemistry
and DAPI staining were performed as previously described
(Phipps et al., 2016) with fluorescent secondary antibodies
(1:1,000) used for visualization (Table 2). To assess Aβ plaque
load in 3- (n = 9), 6 (n = 10) and 12- (n = 8) month-old
APP/PS1 mice, one tissue section between bregma 1.53 mm
and −1.56 mm containing the S1/S2 somatosensory cortex
and the M1/M2 motor cortex from each mouse was subjected
to formic acid antigen retrieval and Aβ labeling with the
anti-6E10 antibody was performed as previously (Phipps et al.,
TABLE 1 | Primary antibodies.
Name Epitope Manufacturer Catalogue number Host species Concentration
H3K4me3 Histone 3, Lysine 4 trimethyl Active Motif (USA) 39160 Rabbit 1:1,000
H3K27me3 Histone 3, Lysine 27 trimethyl Millipore (USA) 07–449 Rabbit 1:1,000
H3K27ac Histone 3, Lysine 27 acetylated Active Motif (USA) 39134 Rabbit 1:1,000
SMI-32 NF-M and NF-H non-phosphorylated Biolegend (USA) SMI-32P Mouse 1:500
Calretinin Calretinin-22K Swant (Switzerland) 6B3 Mouse 1:250
6E10 Purified β-amyloid 1–16 Covance (USA) SIG-39320 Mouse 1:1,000
Synaptophysin Synthetic full-length human synaptophysin Millipore (USA) AB9272 Rabbit 1:200
VGlut1 Recombinant protein aa 456–560 of VGlut1 Synaptic Systems (Germany) 135 303 Rabbit 1:500
VGAT Synthetic peptide aa 75–87 of rat VGAT Synaptic Systems (Germany) 131 003 Rabbit 1:500
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TABLE 2 | Secondary antibodies.
Fluorophore Manufacturer Catalogue number Reactivity Species
Alexa Fluor 594 Invitrogen (USA) A-11023 Anti-rabbit IgG Goat
Alexa Fluor 488 Invitrogen (USA) A-11029 Anti-mouse IgG Goat
2016). To assess presynaptic bouton density one tissue section
containing the somatosensory cortex (S1) from 2- and 12-
month-old wild-type mice (n = 5) were immunolabeled with
synaptophysin, vesicular glutamate transporter 1 (VGlut1) or
vesicular GABA transporter (VGAT, Table 1) as previously
described (Mitew et al., 2013a). The dilution of each primary
antibody was optimized and omitting primary antibodies
eliminated all immunosignal. For information regarding the
specificity of primary antibodies used in this study please refer
to the Supplementary Material.
Microscopy and Analysis
All image analysis was performed blinded tomouse genotype and
age. Full coronal tissue sections were imaged on an Olympus
VS120 slide scanner (U-HGLGPS light source, Olympus,
USA) at 20× optical zoom. Autofocusing was optimized
for either SMI-32 or calretinin labeling, an exposure of
50 ms was used to capture images of SMI-32 and calretinin
labeling, and an exposure of 25 ms was used to capture
images of H3K4me3, H3K27ac and H3K27me3 labeling and
DAPI staining.
To determine whether H3K4me3, H3K27me3 and H3K27ac
were altered in all cortical nuclei across disease progression
in APP/PS1 mice, the percentage of nuclei co-localized with
each histone mark was quantitated in neocortical layers
1–6 and in layer 2/3. In each tissue section, two regions of
interest (ROIs) encompassing layers 1–6 and layers 2/3 of
the neocortex of one hemisphere from the longitudinal fissure
to the rhinal fissure were selected. Both DAPI stained nuclei
and H3K4me3, H3K27me3 and H3K27ac-labeled nuclei were
quantitated in each ROI in Image J with the nucleus counter
plugin [(Szabo and Gulya, 2013; Ioannou et al., 2014); see
Supplementary Figure S1].
To assess alterations in H3K4me3, H3K27ac and H3K27me3,
co-localization in NF-positive pyramidal neurons and
calretinin-labeled interneurons in the cortex of APP/PS1 mice,
50 SMI32-positive pyramidal neurons and 50 calretinin-labeled
interneurons were systematically counted in layers 2/3 of the
M1/M2 motor cortex and S1/S2 somatosensory cortex in one
tissue section from each mouse.
To determine Aβ plaque load tissue sections were imaged
on an Olympus VS120 slide scanner (U-HGLGPS light source,
Olympus, USA) at 20× optical zoom. Autofocusing was
optimized for Aβ labeling and an exposure of 40 ms was
used. A region of interest was drawn to contain all of one
hemisphere of the neocortex dorsal to the rhinal fissure and
thresholded to the labeled signal (FIJI ImageJ). The percentage
area occupied by Aβ was calculated by dividing the total area
occupied by plaques by the total area analyzed as previously
(Fernandez-Martos et al., 2015).
To quantitate presynaptic bouton density regions of interest
were imaged in layer 2/3 of the somatosensory cortex (S1)
from each tissue section (3–5 regions of interest/section)
immunolabeled with synaptophysin, VGlut1 and VGAT.
Image acquisition and synaptic puncta analysis were
performed as previously described (Mitew et al., 2013a).
Briefly, z-stacks of each region of interest were acquired
on a Zeiss LSM510 confocal microscope (Zen software,
Germany), each z-stack was merged into one image, images
were automatically thresholded, processed for Gaussian
blurring and watershed prior to particle analysis being
performed to quantitate synaptic puncta (ImageJ; Mitew
et al., 2013a).
Data analysis was performed in SigmaPlot version 11.0
(Systat Software Inc., Chicago, IL, USA). One way analysis of
variance (ANOVA) with post hoc Holm-Sidak, or a Kruskal-
Wallis one way analysis of ranks with post hoc Holm-Sidak
were employed when comparing more than two experimental
groups depending on the distribution (normality, variance) of
the data. A two-tailed type 3 Student’s t-test was used when
comparing two experimental groups. The statistical test used
for each dataset is detailed in the Results section. A p-value
of <0.05 was used as the definition of statistical significance and
all data are represented as the mean ± the standard error of the
mean (SEM).
Images for Figures
Representative images for figures were taken on an Olympus
VS120 slide scanner (U-HGLGPS light source, Olympus,
USA) or a Perkin Elmer spinning disk confocal microscope
(Zeiss LSM710 laser scanning microscope) and Perkin Elmer’s
velocity software (Perkin Elmer). Brightness and contrast
adjustments were made consistently across all images to
enhance the clarity of images with Image-J and Adobe
Photoshop CS6 (Adobe, CA, USA). Graphs were produced in
GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA,
USA).
RESULTS
No Difference in the Percentage of Nuclei
Labeled With H3K4me3, H3K27me3 or
H3K27ac in the Cortex of APP/PS1 Mice
Compared to Wild-Type Mice
H3K4me3 and H3K27ac labeled approximately 79% of cortical
nuclei and H3K27me3 was present in approximately 67% of
cortical nuclei (Figure 1, Supplementary Table S1). There
was no difference in the density of DAPI-stained nuclei
in layers 1–6 or layers 2/3 of the cortex due to age or
APP/PS1 transgene expression (layers 1–6, Kruskal-Wallis one
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FIGURE 1 | No difference in the percentage of nuclei immunolabeled with H3K4me3, H3K27me3 or H3K27ac in layers 1-6 of the cortex in APP/PS1 mice
compared to wild-type mice. Representative images of coronal sections stained with DAPI (blue, A,C,D,F,G,I) and immunolabeled for H3K4me3 (red, B,C), H3K27ac
(red, E,F) and H3K27me3 (red, H,I) in a 3 month old APP/PS1 mouse (A–C), a 12 month old APP/PS1 mouse (D–F) and a 3 month old wild type (WT) mouse (G–I).
(J) Bar graph displaying the density of DAPI stained nuclei in layers 1-6 of 3-month (3M), 6-month (6M) and 12-month (12M) old WT and APP/PS1 transgenic (TG)
mice. Bar graphs showing the percentage of nuclei co-localized with H3K4me3 (K), H3K27ac (L) and H3K27me3 (M) at 3, 6 and 12 months of age in APP/PS1 and
wild-type mice. All data presented as mean ± standard error of the mean (SEM). Scale bar = 400 µm.
way ANOVA on ranks, Figure 1J; layers 2/3, one way
ANOVA, p > 0.05; Figure 2J). There were no alterations
to the percentage of nuclei immunolabeled with H3K4me3,
H3K27me3 or H3K27ac cortical layers 1–6 (H3K4me3, Kruskal-
Wallis one way ANOVA on ranks; H3K27me3 and H3K27ac,
one way ANOVA; Figure 1) or in layers 2/3 (one way ANOVA,
Figure 2) due to the age or genotype. The Aβ plaque load was
quantitated, and as expected progressively increased with age in
3- (0.21 ± 0.1%), 6- (1.5 ± 0.5%) and 12- (15.3 ± 3.1%) month-
old APP/PS1 mice.
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FIGURE 2 | No change in the proportion of nuclei in layer 2/3 of the cortex co-localized with H3K4me3, H3K27me3 or H3K27ac in APP/PS1 mice vs. wild-type
mice. Example images of areas layer 2/3 stained for DAPI (blue, A,C,D,F,G,I) and immunolabeled for H3K4me3 (red, B,C), H3K27ac (red, E,F) and H3K27me3 (red,
H,I) in a 6 month old WT mouse (A–C), a 6 month old APP/PS1 mouse (D–F) and a 12 month old WT mouse (G–I). Note nuclei positive (arrows) and negative
(arrowheads) for histone mark immunoreactivity. (J) Bar graph displaying the density of nuclei in layer 2/3 of 3-month (3M), 6-month (6M) and 12-month (12M) WT
mice and TG APP/PS1 mice. Bar graphs showing the percentage of nuclei immunoreactive for H3K4me3 (K), H3K27ac (L) and H3K27ac (M). All data presented as
mean ± SEM. Scale bar =50 µm.
No Alteration in the Percentage of Layer
2/3 NF-Labeled Pyramidal Neurons
Co-localized With H3K4me3, H3K27me3 or
H3K27ac in APP/PS1 Mice Compared to
Age-Matched Wild-Type Mice
H3K4me3, H3K27me3 and H3K27ac labeling were nuclear, with
no cytoplasmic immunoreactivity observed either in NF-labeled
pyramidal neurons or in calretinin-positive interneurons of
cortical layer 2/3 (Figure 3). The vast majority (92%–98%) of
NF-positive pyramidal neurons in layer 2/3 exhibited nuclear
immunoreactivity for H3K27ac, H3K4me3 and H3K27me3
(Figure 4, Supplementary Table S1). There was a small
(∼7%), but significant decrease in the percentage of NF-labeled
pyramidal neurons labeled with H3K27ac in 6-month-old
wild-type mice compared to both 3- and 12-month-old
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FIGURE 3 | Nuclear H3K4me3, H3K27me3 and H3K27ac immunolabeling was observed in cortical layer 2/3 calretinin-positive interneurons and neurofilament
(NF)-labeled pyramidal neurons. Representative images of layer 2/3 in a 12 month old WT mouse (A–D) showing NF-labeled pyramidal neurons (A,D green)
co-localized (arrows) with DAPI staining (B,D blue) and H3K27ac immunoreactivity (C,D red). An example image of layer 2/3 in a 3 month old APP/PS1 mouse (E–H)
showing NF-labeled pyramidal neurons (E,H, green) co-localized (arrows) with DAPI staining (F,H, blue) and H3K27me3 labeling (G,H, red). A representative image
layer 2/3 in a 3 month old wild-type mouse (I–L) showing NF-labeled pyramidal neurons (I,L, green) co-localized (arrows) with DAPI (J,L, blue) and
H3K4me3 immunoreactivity (K,L, red). An example image of layer 2/3 of a 3 month old APP/PS1 cortex (M–P) with calretinin-labeled interneurons (M,P green)
co-localized (arrows) with DAPI staining (N,P blue) and H3K27ac immunoreactivity (O,P red). Representative image of layer 2/3 of a 3 month old APP/PS1 mouse
(Q–T) illustrating calretinin-positive interneurons (Q,T green) containing (arrows) DAPI staining (R,T blue) and H3K27me3 labeling (S,T red). An example region of
layer 2/3 of the cortex of a 6 month old wild-type mouse (U–X) showing calretinin-labeled interneurons (U,X green) co-localized (arrows) with DAPI staining (V,X blue)
and H3K4me3 immunopositive nuclei (W,X red). Scale bar = 18 µm.
wild-type mice (One Way ANOVA; p < 0.001; Figure 4G).
There was no alteration in the percentage of NF-positive
pyramidal neurons co-localized with H3K27ac, H3K4me3 or
H3K27me3 in APP/PS1 mice compared to wild-type mice at
3, 6 and 12 months of age (H3K27ac, One Way ANOVA;
H3K4me3 and H3K27me3, Kruskal-Wallis one way ANOVA on
ranks; Figures 4G–I, Supplementary Figures S2, S3). Similarly,
there was no difference between the proportion of NF-labeled
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FIGURE 4 | No difference in the percentage of layer 2/3 NF-labeled pyramidal neurons co-localized with H3K4me3, H3K27me3 or H3K27ac in APP/PS1 vs.
wild-type mice. Representative images of layer 2/3 NF-positive pyramidal neurons (SMI-32, green) stained with DAPI (blue) and labeled for H3K27ac (red, arrows) in
3- (A,D), 6- (B,E) and 12- (C,F) month-old wild-type (A–C) and APP/PS1 (D–F) mice. Bar graphs showing the percentage of NF-positive neuronal nuclei
co-localized with H3K27ac (G), H3K27me3 (H) and H3K4me3 (I) immunolabeling. All data are presented as mean ± SEM. ∗p < 0.05. Scale bars: 25 µm.
pyramidal neurons that were immunoreactive for H3K4me3 or
H3K27me3 in wild-type mice at 3, 6 and 12 months of age
(Kruskal-Wallis one-way ANOVA on ranks; Figures 4H,I).
No Change in the Proportion of Layer
2/3 Calretinin-Labeled Interneurons
Co-localized With H3K27me3, H3K4me3 or
H3K27ac in APP/PS1 Compared to
Wild-Type Mice
The vast majority (∼80%–95%) of layer 2/3 calretinin-
positive interneurons were immunoreactive for H3K27me3,
H3K4me3 or H3K27ac (Figure 5, Supplementary Table
S1). Interestingly, there was an increase (∼20%) in the
percentage of calretinin-positive interneurons immunolabeled
with H3K27me3 in 12-month-old APP/PS1 mice compared to
both 3- and 6-month-old APP/PS1 mice (One Way ANOVA,
p< 0.001; Figure 5G). There was no difference in the percentage
of layer 2/3 calretinin-labeled interneurons co-localized with
H3K27me3, H3K4me3 or H3K27ac between APP/PS1 and
wild-type mice at 3, 6 and 12 months of age (H3K27me3,
One way ANOVA; H3K4me3 and H3K27ac, Kruskal-Wallis
one way ANOVA on ranks; Figures 5G–I, Supplementary
Figures S4, S5). While previous work from our laboratory
revealed that excitatory, but not inhibitory, presynaptic puncta
are lost adjacent to Aβ plaques (Mitew et al., 2013a), we
detected no difference in the density of presynaptic puncta
containing synaptophysin (all presynaptic puncta), VGlut1
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FIGURE 5 | No difference in the percentage of layer 2/3 calretinin-positive interneurons co-localized with H3K27me3, H3K4me3 or H3K27ac in APP/PS1 vs.
wild-type mice. Representative images of layer 2/3 calretinin-positive interneurons (green), stained with DAPI (blue) and labeled with H3K27me3 (red, arrows) in 3-
(A,D), 6- (B,E) and 12- (C,F) month-old wild-type (A–C) and APP/PS1 (D–F) mice. Bar graphs showing the percentage of calretinin-labeled interneurons
co-localized with H3K27me3 (G), H3K4me3 (H) and H3K27ac (I). All data are presented as mean ± SEM. ∗p < 0.05. Scale bars 25 µm.
(excitatory presynaptic puncta) or VGAT (inhibitory presynaptic
puncta) between 2-month-old and 12-month-old wild-type mice
(Supplementary Figure S6, Table S1).
When NF-positive pyramidal neurons and calretinin-labeled
interneurons were compared, a lower percentage of calretinin-
labeled interneurons co-localized with H3K27me3 compared to
NF-positive pyramidal neurons in 3- and 6-month old wild-type
mice (p < 0.05, student’s t-test). There was no difference in the
proportion of NF-immunoreactive pyramidal neurons compared
to calretinin-labeled interneurons co-labeled with H3K4me3,
H3K27ac in 3-, 6- and 12-month-old wild-type mice.
DISCUSSION
This is the first study to investigate the H3K4me3, H3K27ac
and H3K27me3 histone marks in AD in specific subsets of
neurons that are selectively vulnerable and resistant to AD
pathology. We did not detect any global alterations in H3K4me3,
H3K27ac or H3K27me3 across a time course in wild-type
compared to APP/PS1 mice, in the nuclei of all cortical cell
types, AD susceptible NF-positive pyramidal neurons or in
AD-resilient calretinin-interneurons. Mastroeni et al. (2015) also
detected no change in the overall protein level of H3K4me3 in
the medial temporal gyrus of human AD cases compared
to controls. However, the same study discovered abnormal
H3K4me3 loss in the nucleus and gain of H3K4me3 in the
cytoplasm in human AD cases compared to controls (Mastroeni
et al., 2015). Themislocalized cytoplasmicH3K4me3 co-localized
with pre-tangles and NFTs in late AD cases (Mastroeni
et al., 2015). The authors also reported a loss of nuclear
H3K4me3 in hippocampal subregions in the 3×Tg AD mouse
model (which develop plaques and NFTs), but no cytoplasmic
H3K4me3 immunoreactivity (Mastroeni et al., 2015). We did not
observe any cytoplasmic accumulation or nuclear depletion of
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H3K4me3 in the cortex of APP/PS1 mice. These data suggest
that H3K4me3 mislocalization may be region specific, and its
occurrence in human AD, but not AD mouse models indicates
that it could be a species or time-dependent process. It should
be noted that APP/PS1 mice do not develop tau pathology, and
so it is possible that the accumulation of abnormal tau and the
deposition of NFTsmay drive global changes andmislocalization
of H3K4me3, H3K27ac and H3K27me3. Furthermore, this study
only informs on the global level and subcellular localization
of H3K4me3, H3K27ac and H3K427me3 and does not rule
out robust global changes in other cell populations or at
specific gene loci. Indeed, chromatin immunoprecipitation
sequencing (ChIP-seq) data from AD cases and mouse models of
neurodegeneration show that histone mark alterations certainly
occur at specific loci in AD compared to control tissue
(Gräff et al., 2012; Benito et al., 2015; Gjoneska et al., 2015;
Nativio et al., 2018).
Our study captured age-related changes in histone
marks in wild-type mice. There was a ∼20% increase
in the percentage of calretinin-labeled interneurons with
H3K27me3 immunoreactivity at 12 months of age vs. 3 and
6 months of age, suggesting increased repression of the genome
in calretinin-positive interneurons with aging. A previous study
reported a decrease in H3K4me3 in whole brain homogenate
in aged vs. young mice (Gong et al., 2015), while analysis
of homogenate from rat hippocampal subregions showed
increased H3K4me3 in the CA1 and CA3, but not in the
dentate gyrus with age (Morse et al., 2015). Furthermore, aged
(>60 years) human prefrontal cortex neurons exhibited a loss
of H3K4me3 at 556 genes and a gain of H3K4me3 at 101 genes
when compared to young (<1 year) neurons (Cheung et al.,
2010). Taken together these data suggest that H3K4me3 likely
alters across the course of healthy aging in a complex manner
that is both region- and neuronal subtype-specific. The current
study also detected a small but significant decrease (∼7%) in
the proportion of NF-positive pyramidal neurons co-localized
with H3K27ac at 6 months of age compared to both 3 and
12 months of age. In keeping with our data, a study of whole
brain homogenate did not detect any change in the overall
level of H3K27ac between 3-month-old and 22-month-old mice
(Gong et al., 2015). The physiological impact of a transient
15% decrease in the proportion of NF-labeled pyramidal
neurons immunoreactive for H3K27ac at 6 months of age
is currently unknown; the subset of neurons, genetic loci at
which H3K27ac decreases and alterations in other epigenetic
marks and modifiers would also need to be considered. It
should also be noted that the interpretation of changes in
H2K27ac levels may not be straightforward, with a recent
study suggesting that genes that are up-regulated with age
are characterized by a decrease in both activating H3K27ac
at promoters and repressive H3K27ac within gene bodies
(Cheng et al., 2018). Interestingly, no loss of presynaptic
boutons (including excitatory or inhibitory subsets) was
detected in 12-month-old wild-type compared to 2-month-old
wild-type mice in the current study. These data, together with
previous work demonstrating plaque-associated synapse loss
in 10–12-month-old APP/PS1 mice (Mitew et al., 2013a),
suggest that the global changes in H3K27me3, H3K27ac and
H3K4me3 levels in NF-labeled pyramidal neurons or calretinin-
positive interneurons do not correlate with synapse loss in
APP/PS1 or wild-type mice.
This study also identified inherent differences in
H3K27me3 expression between calretinin-labeled interneurons
and NF-immunoreactive pyramidal neurons. The lower
expression of H3K27me3 in calretinin-positive interneurons
suggesting a less repressed epigenome in this interneuron
subpopulation. Several studies have documented distinct
epigenetic profiles for excitatory and inhibitory neurons
to date (Mo et al., 2015; Kozlenkov et al., 2016; Luo et al.,
2017; Gasparoni et al., 2018). In keeping with our data,
DNA methylation data in human cortex also identified
decreased methylation of CpG sites in inhibitory neurons
compared to excitatory neurons (Kozlenkov et al., 2016).
However, excitatory neurons from mouse exhibited increased
chromatin accessibility and increased DNA hypomethylation
compared to different murine inhibitory interneuron subtypes
(parvalbumin- and vasoactive intestinal peptide-interneurons;
Mo et al., 2015). We have also previously detected differences
in 5mC and 5hmC labeling in NF-positive pyramidal neurons
and calretinin-immunoreactive interneurons in the human
brain (Phipps et al., 2016). Differences in the epigenetic
landscape of neuronal subtypes are to be expected, especially
considering the vast diversity of neuronal function and
plasticity in the brain. In fact, recent t-SNE analysis of
single-neuron DNA methylation data have predicted that
there are 16 distinct subpopulations of neurons in the frontal
cortex of the mouse and 21 in the human frontal cortex (Luo
et al., 2017), indicating more extensive functional diversity
and network complexity in the cortex than had previously
been predicted.
The use of the APP/P1 mouse model is a limitation of the
current study as it does not develop the neurofibrillary pathology
or overt cell loss that occurs in human AD. Thus, we cannot
rule out the possibility that global levels of H3K4me3, H3K27ac
or H2K37me3 may alter in disease-resistant and–vulnerable
subpopulations of neurons in the presence of tau pathology.
Indeed, Mastroeni et al. (2015) described abnormal translocation
of H3K4me3 from the nucleus to the cytoplasm that correlated
with tau pathology load in the middle temporal gyrus of AD
cases. Recent research also reported that tau load, but not Aβ
load, correlated with H3K9ac marking in the prefrontal cortex
in AD and demonstrated that tau overexpression alters spatial
chromatin structure (Klein et al., 2019). Furthermore, the current
study uses immunohistochemistry, and while this technique can
provide valuable information regarding global levels of histone
marks and their intracellular location in subtypes of neurons
it does not provide base pair level resolution of histone mark
alterations across the genome.
CONCLUSION
We present data, for the first time, describing no global
alterations in the proportion of AD-susceptible NF-labeled
pyramidal neurons or AD-resistant calretinin-positive
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interneurons co-localized with the H3K4me3, H3K27ac
and H3K27me3 histone marks across a time course in
APP/PS1 and wild-type mice. We report alterations in the
global levels of H3K27ac in NF-positive pyramidal neurons
and in H3K27me3 in calretinin-immunoreactive interneurons
with age. Our data suggest that amyloid deposition does
not impact the global levels of H3K4me3, H3K27ac and
H3K27me3 in the two neuronal populations and at the time
points examined in this study. However, it is important
to note that the global levels of histone marks can remain
unaltered concomitant with dramatic changes at specific loci;
as alterations of histone marks at specific gene loci certainly
occurs in AD (Benito et al., 2015; Gjoneska et al., 2015;
Nativio et al., 2018).
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